Montelucaste Generis (Montelukast)

Montelukast, the active ingredient in Montelucaste Generis, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children. By blocking cysteinyl leukotriene receptors, it helps reduce airway narrowing and inflammation, improving breathing and symptom control.

GNH USA supplies Montelucaste Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to treat respiratory conditions mediated by leukotriene‑driven inflammation. - Asthma: improves control of persistent asthma and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache reported. - Upper respiratory infection: symptoms such as sore throat or nasal congestion. - Cough: occasional non‑productive cough. - Abdominal pain: mild stomach discomfort. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, anxiety, depression, or suicidal thoughts. - Allergic reactions: rash, urticaria, or angioedema. - Hepatotoxicity: elevated liver enzymes or jaundice. - Churg‑Strauss syndrome: rare vasculitic condition. - Anaphylaxis: severe, life‑threatening allergic response.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess asthma severity: confirm diagnosis and level of control before initiating therapy. - Monitor psychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Evaluate liver function: consider baseline tests in patients with hepatic impairment. - Use in pregnancy: prescribe only if potential benefit justifies potential risk, as safety data are limited. - Drug interactions: review concomitant medications for known interactions. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of montelukast. - Rifampin: induces metabolism leading to decreased therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): may increase risk of neuropsychiatric side effects. - Antihistamines: additive effect on sedation may occur. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.